NuCana dives on scrapping biliary tract cancer drug trial
02/03/2022 22:09
** Shares of the drug developer NCNA.O fall 56.7% to $1.25
in extended trading
** Co is discontinuing late-stage study testing its
experimental treatment Acelarin in combination with chemotherapy
drug cisplatin in patients with advanced biliary tract cancer
urn:newsml:reuters.com:*:nFWN2V512T
** Decision was made on recommendation of an independent
data monitoring committee, which conducted a futility assessment
** The panel concluded that Acelarin plus cisplatin was
unlikely to achieve its main goal of demonstrating at least a
2.2-month improvement in overall survival as compared to
standard of care
** Co will carefully review these data to determine future
potential development pathways for Acelarin - NCNA
** Stock gained ~24% YTD, as of last close
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))